Surrogate Endpoints for Late Kidney Transplantation Failure
暂无分享,去创建一个
K. Budde | A. Loupy | R. Oberbauer | S. Schneeberger | U. Heemann | M. Naesens | D. Glotz | L. Pengel | M. Bellini | J. Grinyó | I. Jochmans | L. Hilbrands | M. Reinders | J. Grinyo
[1] K. Budde,et al. Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation , 2022, Transplant International.
[2] K. Budde,et al. Allograft Function as Endpoint for Clinical Trials in Kidney Transplantation , 2022, Transplant International.
[3] S. Chadban,et al. Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study , 2021, BMJ Open.
[4] K. Budde,et al. Exploring the Complexity of Death-Censored Kidney Allograft Failure , 2021, Journal of the American Society of Nephrology : JASN.
[5] N. Kamar,et al. An extension of the RITUX‐ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody‐mediated rejection after renal transplantation , 2020, Transplant international : official journal of the European Society for Organ Transplantation.
[6] E. Lerut,et al. Assessing the Complex Causes of Kidney Allograft Loss , 2020, Transplantation.
[7] Olivier Aubert,et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study , 2019, BMJ.
[8] L. Ruilope. Faculty Opinions recommendation of Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[9] T. Srinivas,et al. Development and future deployment of a 5 years allograft survival model for kidney transplantation , 2019, Nephrology.
[10] I. König,et al. Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study. , 2019, Clinical journal of the American Society of Nephrology : CJASN.
[11] X. Jouven,et al. Archetype Analysis Identifies Distinct Profiles in Renal Transplant Recipients with Transplant Glomerulopathy Associated with Allograft Survival. , 2019, Journal of the American Society of Nephrology : JASN.
[12] Pengfei Guo,et al. A meta-analysis of randomized controlled trials , 2019, Medicine.
[13] M. Pfeffer,et al. Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[14] J. Craig,et al. Range and Consistency of Outcomes Reported in Randomized Trials Conducted in Kidney Transplant Recipients: A Systematic Review , 2018, Transplantation.
[15] M. Bots,et al. A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival. , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] E. Lerut,et al. Histological picture of antibody‐mediated rejection without donor‐specific anti‐HLA antibodies: Clinical presentation and implications for outcome , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] F. Claas,et al. Technical challenges and clinical relevance of single antigen bead C1q/C3d testing and IgG subclass analysis of human leukocyte antigen antibodies , 2018, Transplant international : official journal of the European Society for Organ Transplantation.
[18] M. Mengel,et al. Meeting report of the STAR—Sensitization in Transplantation Assessment of Risk: Naïve Abdominal Transplant Organ subgroup focus on kidney transplantation , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[19] J. Craig,et al. Renal transplant outcomes and de novo donor-specific anti-human leukocyte antigen antibodies: a systematic review , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] S. Chadban,et al. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. , 2018, Journal of the American Society of Nephrology : JASN.
[21] X. Jouven,et al. Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis , 2018, PLoS medicine.
[22] H. Meier‐Kriesche,et al. De novo donor‐specific antibodies in belatacept‐treated vs cyclosporine‐treated kidney‐transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT‐EXT studies , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[23] J. Pascual,et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double‐blind clinical trial , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[24] Rubin Zhang. Donor-Specific Antibodies in Kidney Transplant Recipients. , 2018, Clinical journal of the American Society of Nephrology : CJASN.
[25] M. Posch,et al. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. , 2017, Journal of the American Society of Nephrology : JASN.
[26] P. Reinke,et al. Donor–Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor‐Specific HLA Antibodies Following Renal Transplantation , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[27] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[28] P. Nickerson,et al. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. , 2017, Journal of the American Society of Nephrology : JASN.
[29] H. Meier‐Kriesche,et al. Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[30] M. Tonelli,et al. Albuminuria and posttransplant chronic kidney disease stage predict transplant outcomes. , 2017, Kidney international.
[31] Pierre Marquet,et al. An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies , 2017, PloS one.
[32] F. Bemelman,et al. Early Conversion From Calcineurin Inhibitor‐ to Everolimus‐Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[33] P. Grimbert,et al. mTOR inhibitors and risk of chronic antibody‐mediated rejection after kidney transplantation: where are we now? , 2017, Transplant international : official journal of the European Society for Organ Transplantation.
[34] J. Kaldor,et al. A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (Oral Mouthwash use to Eradicate GonorrhoeA) study protocol , 2017, BMC Infectious Diseases.
[35] B. Banas,et al. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[36] T. Srinivas,et al. Big Data, Predictive Analytics, and Quality Improvement in Kidney Transplantation: A Proof of Concept , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[37] M. Stegall,et al. Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction. , 2017, Transplantation.
[38] Christine A. White,et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. , 2016, The lancet. Diabetes & endocrinology.
[39] M. Stegall,et al. Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[40] M. Stegall,et al. Predicting Individual Renal Allograft Outcomes Using Risk Models with 1-Year Surveillance Biopsy and Alloantibody Data. , 2016, Journal of the American Society of Nephrology : JASN.
[41] L. Rostaing,et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. , 2016, The New England journal of medicine.
[42] J. Radhakrishnan,et al. Proteinuria as a surrogate marker for renal outcome: are we there yet? , 2015, Kidney international.
[43] D. Mandelbrot,et al. Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[44] P. Nickerson,et al. Rates and Determinants of Progression to Graft Failure in Kidney Allograft Recipients With De Novo Donor‐Specific Antibody , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[45] W. Arns,et al. Determination of unacceptable HLA antigen mismatches in kidney transplant recipients: recommendations of the German Society for Immunogenetics. , 2015, Tissue antigens.
[46] E. D. Gregorio,et al. The path forward. , 2015 .
[47] L. Rostaing,et al. Fibrosis Progression According to Epithelial‐Mesenchymal Transition Profile: A Randomized Trial of Everolimus Versus CsA , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[48] A. Konvalinka,et al. Utility of HLA Antibody Testing in Kidney Transplantation. , 2015, Journal of the American Society of Nephrology : JASN.
[49] X. Jouven,et al. Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. , 2015, Journal of the American Society of Nephrology : JASN.
[50] F. Lehner,et al. Five‐Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[51] A. Cherukuri,et al. Predicting 5-year risk of kidney transplant failure: a prediction instrument using data available at 1 year posttransplantation. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[52] G. Opelz,et al. Association Between Steroid Dosage and Death With a Functioning Graft After Kidney Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[53] D. Anglicheau,et al. Transplantation: Proteinuria in kidney transplantation: an ongoing story , 2013, Nature Reviews Nephrology.
[54] B. Sharma,et al. An Open Label Randomised Controlled Trial of Probiotics for Primary Prophylaxis of Hepatic Encephalopathy in Patients with Cirrhosis , 2013 .
[55] L. Ratner,et al. Donor-specific antibodies adversely affect kidney allograft outcomes. , 2012, Journal of the American Society of Nephrology : JASN.
[56] P. Nickerson,et al. Evolution and Clinical Pathologic Correlations of De Novo Donor‐Specific HLA Antibody Post Kidney Transplant , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[57] G. Remuzzi,et al. Proteinuria should be used as a surrogate in CKD , 2012, Nature Reviews Nephrology.
[58] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[59] G. L’italien,et al. Use of 12-Month Renal Function and Baseline Clinical Factors to Predict Long-Term Graft Survival: Application to BENEFIT and BENEFIT-EXT Trials , 2012, Transplantation.
[60] D. Kuypers,et al. Diagnosis and prevention of chronic kidney allograft loss , 2011, The Lancet.
[61] J. Cooper,et al. Inferior Kidney Allograft Outcomes in Patients With De Novo Donor-Specific Antibodies Are Due to Acute Rejection Episodes , 2011, Transplantation.
[62] Atholl Johnston,et al. Development and evaluation of a composite risk score to predict kidney transplant failure. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[63] Thomas Becker,et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial , 2011, The Lancet.
[64] N. Kamar,et al. Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies , 2010, Transplantation.
[65] Yohann Foucher,et al. A clinical scoring system highly predictive of long-term kidney graft survival. , 2010, Kidney international.
[66] Klemens Budde,et al. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk , 2010, Transplant international : official journal of the European Society for Organ Transplantation.
[67] A. Israni,et al. A simple tool to predict outcomes after kidney transplant. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[68] S. Alexander,et al. Rejection of the kidney allograft. , 2010, The New England journal of medicine.
[69] Dominique Charron,et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. , 2010, Journal of the American Society of Nephrology : JASN.
[70] R. Schmieder,et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[71] P. Reinke,et al. Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal Allografts , 2009, Transplantation.
[72] M. Stegall,et al. Identifying Specific Causes of Kidney Allograft Loss , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[73] M. Mézard,et al. An ongoing story , 2009 .
[74] T. Larson,et al. Proteinuria After Kidney Transplantation, Relationship to Allograft Histology and Survival , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[75] H. Nivet,et al. Urinary Albumin Excretion and the Risk of Graft Loss and Death in Proteinuric and Non‐proteinuric Renal Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[76] M. Zeier,et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. , 2006, Journal of the American Society of Nephrology : JASN.
[77] H. Meier‐Kriesche,et al. Poor Predictive Value of Serum Creatinine for Renal Allograft Loss , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[78] P. Nickerson,et al. Pre‐Transplant Assessment of Donor‐Reactive, HLA‐Specific Antibodies in Renal Transplantation: Contraindication vs. Risk , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[79] M. Meade,et al. A critical appraisal and systematic review of illness severity scoring systems in the intensive care unit , 1995 .
[80] P. Terasaki,et al. Significance of the positive crossmatch test in kidney transplantation. , 1969, The New England journal of medicine.
[81] J. Routy,et al. Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation , 2019, Medicine.
[82] M. Tonelli,et al. Influence of Mortality on Estimating the Risk of Kidney Failure in People with Stage 4 CKD , 2019 .
[83] P. V. D. van der Boog,et al. Medication non-adherence after kidney transplantation: A critical appraisal and systematic review. , 2019, Transplantation reviews.
[84] K. Leffondré,et al. Risk prediction models for graft failure in kidney transplantation: a systematic review , 2017 .
[85] G. Knoll,et al. Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[86] E. Lerut,et al. Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure: An Observational Cohort Study. , 2016, Journal of the American Society of Nephrology : JASN.
[87] Melanie Volkamer,et al. Proof of Concept , 2009 .